After signing up, you'll start to receive regular news updates from us.
Axela Biosensors Launches the dotLab™ System
Complete the form below to unlock access to ALL audio articles.
Axela Biosensors inc. have announced the successful launch of its dotLab System at Drug Discovery Technology 2006, held in Boston on August 7-10.
The dotLab System aims to provide the drug discovery, biomarker validation and translational research markets with an affordable, benchtop platform for protein characterization and biomolecular interaction monitoring.
The system accelerates immunoassay development and is able to contribute at each stage of the process including reagent characterization, antibody pairing and cross reactivity studies.
Analysis is performed on dotLab Sensors, which utilize Axela's core Diffractive Optics Technology (dot™). This novel biosensor brings together two mature, well-understood technologies: grating-based light diffraction and immobilized capture surfaces.
This combination produces a sensitive and very simple technique for the detection of molecular binding events without the use of fluorescent labels.
Because the system's illumination and detection beams never pass through the sample, the technology is ideal for the detection of proteins in complex biological samples.
A variety of dotLab Sensor surfaces are available to provide broad application coverage including: Avidin, Protein G, Goat anti-mouse Fc and Amine-reactive surfaces.
Axela is actively developing additional immobilization chemistries and multiplex format sensors.
"We are excited to provide an affordable benchtop solution that addresses the bottlenecks faced by researchers attempting to convert biomarker discoveries into functional assays," said Rocky Ganske, President and CEO of Axela Biosensors.
"Current collaborators have been impressed with the effectiveness of the dotLab System's real-time interaction monitoring that has resulted in rapid assay development. The ability to detect low abundance proteins directly in samples such as cell lysates, serum, plasma, or blood has been identified as an additional benefit.
The unique ability of our platform to contribute throughout the entire therapeutic or diagnostic pipeline, from reagent qualification through clinical trials, will fuel our expansion into the larger clinical diagnostics market."
